Literature DB >> 35782821

Molecular Profile and Clinico-pathological Characteristics of Breast Cancer in Central India: First Investigative Report.

Aaryan Anand1, Arpan Mishra1, Harikrishna Damde1, Arjun Saxena1, Sanjay Kumar Yadav1, Dhananjaya Sharma1.   

Abstract

Stage at presentation and molecular profile are the two most important factors affecting breast cancer prognosis. This is the first study on molecular breast cancer subtypes from Central India. We prospectively reviewed 260 consecutive breast cancer patients diagnosed at the Department of Surgery, Government NSCB Medical College, Jabalpur (MP), between January 2017 and December 2020. Clinico-pathological and molecular profiles and their associations with the characteristics of the tumor were analyzed. The median age at diagnosis was 44.7 years (range 21-93). Eleven percent (n = 11) were in clinical stage I, 12.7% (n = 12) were in stage II, 56% (n = 146) in stage III, and 20% (n = 52) were in stage IV. Metastatic lymph node positivity rate was 85% at the time of diagnosis. Luminal subtype was present in 50% (n = 131), Her 2 neu-enriched type in 21.5% (n = 55), and triple-negative subtype in 28.5% (n = 74). A stronger association was observed for each increasing clinical stage for Her 2 neu-enriched and triple-negative breast cancer (TNBC) but not luminal-type tumors. For grade of tumors, patients with luminal subtype had a higher percentage of lower grades (p = .001); however, Her 2-enriched and TNBC had higher proportion of grade III tumors (for Her 2-enriched p = .04, TNBC p = .001). In Central India, like other regions of India, breast cancer occurs at an earlier age and is diagnosed at a more advanced stage. In this region, pre-menopausal breast cancer is more common than post-menopausal and TNBC tumors have similar incidence in pre-menopausal and postmenopausal women. © Indian Association of Surgical Oncology 2022.

Entities:  

Keywords:  Breast cancer; Estrogen receptor; Her 2 neu receptor; Molecular profile; Progesterone receptor

Year:  2022        PMID: 35782821      PMCID: PMC9240130          DOI: 10.1007/s13193-022-01502-0

Source DB:  PubMed          Journal:  Indian J Surg Oncol        ISSN: 0975-7651


  15 in total

1.  Fungating Breast Cancer: Experience in Low and Middle Income Country.

Authors:  Raouef Ahmed Bichoo; Sanjay Kumar Yadav; Anjali Mishra; Punita Lal; Gyan Chand; Gaurav Agarwal; Amit Agarwal; Saroj K Mishra
Journal:  Indian J Surg Oncol       Date:  2020-02-19

Review 2.  Epidemiology, biology, and treatment of triple-negative breast cancer in women of African ancestry.

Authors:  Abenaa M Brewster; Mariana Chavez-MacGregor; Powel Brown
Journal:  Lancet Oncol       Date:  2014-11-24       Impact factor: 41.316

3.  Estrogen and Progesterone Receptor Testing in Breast Cancer: American Society of Clinical Oncology/College of American Pathologists Guideline Update.

Authors:  Kimberly H Allison; M Elizabeth H Hammond; Mitchell Dowsett; Shannon E McKernin; Lisa A Carey; Patrick L Fitzgibbons; Daniel F Hayes; Sunil R Lakhani; Mariana Chavez-MacGregor; Jane Perlmutter; Charles M Perou; Meredith M Regan; David L Rimm; W Fraser Symmans; Emina E Torlakovic; Leticia Varella; Giuseppe Viale; Tracey F Weisberg; Lisa M McShane; Antonio C Wolff
Journal:  Arch Pathol Lab Med       Date:  2020-01-13       Impact factor: 5.534

4.  Estrogen, progesterone and HER2 receptor expression in breast tumors of patients, and their usage of HER2-targeted therapy, in a tertiary care centre in India.

Authors:  J Ghosh; S Gupta; S Desai; T Shet; S Radhakrishnan; P Suryavanshi; V Parmar; R Jalali; G Goyal; R Hawaldar; A Patil; N Nair; R A Badwe
Journal:  Indian J Cancer       Date:  2011 Oct-Dec       Impact factor: 1.224

5.  Breast Cancer-Major changes in the American Joint Committee on Cancer eighth edition cancer staging manual.

Authors:  Armando E Giuliano; James L Connolly; Stephen B Edge; Elizabeth A Mittendorf; Hope S Rugo; Lawrence J Solin; Donald L Weaver; David J Winchester; Gabriel N Hortobagyi
Journal:  CA Cancer J Clin       Date:  2017-03-14       Impact factor: 508.702

6.  Triple negative breast cancer in people of North East India: critical insights gained at a regional cancer centre.

Authors:  Mousumi Sharma; Jagannath Dev Sharma; Anupam Sarma; Shiraj Ahmed; Amal Chandra Kataki; Rahul Saxena; Dilutpal Sharma
Journal:  Asian Pac J Cancer Prev       Date:  2014

7.  A clinical and pathological study of triple negative breast carcinoma: experience of a tertiary care centre in eastern India.

Authors:  Santanu Sen; Rajarshi Gayen; Soumen Das; Sanjay Maitra; Amitesh Jha; Manisha Mahata
Journal:  J Indian Med Assoc       Date:  2012-10

8.  Hormone receptors over the last 8 years in a cancer referral center in India: what was and what is?

Authors:  Tanuja Shet; Atin Agrawal; Mandar Nadkarni; Mahendra Palkar; Rohini Havaldar; Vani Parmar; Rajendra Badwe; R F Chinoy
Journal:  Indian J Pathol Microbiol       Date:  2009 Apr-Jun       Impact factor: 0.740

Review 9.  Prevalence of Molecular Subtypes of Breast Cancer in India: a Systematic Review and Meta-analysis.

Authors:  Pavan Kumar Jonnada; Cherukuru Sushma; Madhuri Karyampudi; Anvesh Dharanikota
Journal:  Indian J Surg Oncol       Date:  2020-10-28

10.  Should molecular subtype be recommended as one of the selection criteria for accelerated partial breast irradiation? Preliminary results from an Asian cohort.

Authors:  Tabassum Wadasadawala; Monidipa Mondal; Siji Nojin Paul; Vani Parmar; Nita Nair; Tanuja Shet; Sangeeta Desai; Sudeep Gupta; Rajiv Sarin
Journal:  J Contemp Brachytherapy       Date:  2018-02-28
View more

北京卡尤迪生物科技股份有限公司 © 2022-2023.